摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[[2-[(2S,4R)-1-[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]-4-[(7-methoxy-2-phenyl-4-quinolyl)oxy]pyrrolidin-2-yl]acetyl]amino]cyclopropanecarboxylic acid | 1040233-68-8

中文名称
——
中文别名
——
英文名称
1-[[2-[(2S,4R)-1-[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]-4-[(7-methoxy-2-phenyl-4-quinolyl)oxy]pyrrolidin-2-yl]acetyl]amino]cyclopropanecarboxylic acid
英文别名
1-[[2-[(2S,4R)-4-(7-methoxy-2-phenylquinolin-4-yl)oxy-1-[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]pyrrolidin-2-yl]acetyl]amino]cyclopropane-1-carboxylic acid
1-[[2-[(2S,4R)-1-[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]-4-[(7-methoxy-2-phenyl-4-quinolyl)oxy]pyrrolidin-2-yl]acetyl]amino]cyclopropanecarboxylic acid化学式
CAS
1040233-68-8
化学式
C36H44N4O8
mdl
——
分子量
660.767
InChiKey
WSXCDSDUNJEQRQ-QXTPGCHQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    48
  • 可旋转键数:
    13
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    156
  • 氢给体数:
    3
  • 氢受体数:
    9

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    β-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors
    摘要:
    In an effort to develop a new type of HCV NS3 peptidomimetic inhibitor, a series of tripeptide inhibitors incorporating a mix of alpha- and beta-amino acids has been synthesized. To understand the structural implications of beta-amino acid substitution, the P-1, P-2, and P-3 positions of a potent tripeptide scaffold were scanned and combined with carboxylic acid and acyl sulfonamide C-terminal groups. Inhibition was evaluated and revealed that the structural changes resulted in a loss in potency compared with the a- peptide analogues. However, several compounds exhibited mu M potency. Inhibition data were compared with modeled ligand-protein binding poses to understand how changes in ligand structure affected inhibition potency. The P-3 position seemed to be the least sensitive position for beta-amino acid substitution. Moreover, the importance of a proper oxyanion hole interaction for good potency was suggested by both inhibition data and molecular modeling. To gain further insight into the structural requirements for potent inhibitors, a three-dimensional quantitative structure-activity relationship (3D- QSAR) model has been constructed using comparative molecular field analysis (CoMFA). The most predictive CoMFA model has q(2) = 0.48 and r(pred)(2) = 0.68. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2008.04.005
  • 作为产物:
    描述:
    methyl 1-(2-((2S,4R)-1-((tert-butoxycarbonyl)-L-valyl)-4-((7-methoxy-2-phenylquinolin-4-yl)oxy)pyrrolidin-2-yl)acetamido)cyclopropane-1-carboxylate 在 lithium hydroxide 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 4.0h, 生成 1-[[2-[(2S,4R)-1-[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]-4-[(7-methoxy-2-phenyl-4-quinolyl)oxy]pyrrolidin-2-yl]acetyl]amino]cyclopropanecarboxylic acid
    参考文献:
    名称:
    β-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors
    摘要:
    In an effort to develop a new type of HCV NS3 peptidomimetic inhibitor, a series of tripeptide inhibitors incorporating a mix of alpha- and beta-amino acids has been synthesized. To understand the structural implications of beta-amino acid substitution, the P-1, P-2, and P-3 positions of a potent tripeptide scaffold were scanned and combined with carboxylic acid and acyl sulfonamide C-terminal groups. Inhibition was evaluated and revealed that the structural changes resulted in a loss in potency compared with the a- peptide analogues. However, several compounds exhibited mu M potency. Inhibition data were compared with modeled ligand-protein binding poses to understand how changes in ligand structure affected inhibition potency. The P-3 position seemed to be the least sensitive position for beta-amino acid substitution. Moreover, the importance of a proper oxyanion hole interaction for good potency was suggested by both inhibition data and molecular modeling. To gain further insight into the structural requirements for potent inhibitors, a three-dimensional quantitative structure-activity relationship (3D- QSAR) model has been constructed using comparative molecular field analysis (CoMFA). The most predictive CoMFA model has q(2) = 0.48 and r(pred)(2) = 0.68. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2008.04.005
点击查看最新优质反应信息

文献信息

  • β-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors
    作者:Johanna Nurbo、Shane D. Peterson、Göran Dahl、U. Helena Danielson、Anders Karlén、Anja Sandström
    DOI:10.1016/j.bmc.2008.04.005
    日期:2008.5
    In an effort to develop a new type of HCV NS3 peptidomimetic inhibitor, a series of tripeptide inhibitors incorporating a mix of alpha- and beta-amino acids has been synthesized. To understand the structural implications of beta-amino acid substitution, the P-1, P-2, and P-3 positions of a potent tripeptide scaffold were scanned and combined with carboxylic acid and acyl sulfonamide C-terminal groups. Inhibition was evaluated and revealed that the structural changes resulted in a loss in potency compared with the a- peptide analogues. However, several compounds exhibited mu M potency. Inhibition data were compared with modeled ligand-protein binding poses to understand how changes in ligand structure affected inhibition potency. The P-3 position seemed to be the least sensitive position for beta-amino acid substitution. Moreover, the importance of a proper oxyanion hole interaction for good potency was suggested by both inhibition data and molecular modeling. To gain further insight into the structural requirements for potent inhibitors, a three-dimensional quantitative structure-activity relationship (3D- QSAR) model has been constructed using comparative molecular field analysis (CoMFA). The most predictive CoMFA model has q(2) = 0.48 and r(pred)(2) = 0.68. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(-)-N-[(2S,3R)-3-氨基-2-羟基-4-苯基丁酰基]-L-亮氨酸甲酯 鹅肌肽硝酸盐 非诺贝特杂质C 霜霉灭 阿洛西克 阿沙克肽 阿拉泊韦 门冬氨酸缩合物 铬酸酯(1-),二[3-[(4,5-二氢-3-甲基-5-羰基-1-苯基-1H-吡唑-4-基)偶氮]-4-羟基-N-苯基苯磺酰氨酸根(2-)]-,钠 钠(6S,7S)-3-(乙酰氧基甲基)-8-氧代-7-[(1H-四唑-1-基乙酰基)氨基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸酯 金刚西林 醋酸胃酶抑素 酪蛋白 酪氨酰-脯氨酰-N-甲基苯丙氨酰-脯氨酰胺 透肽菌素A 连氮丝菌素 远霉素 达福普丁甲磺酸复合物 达帕托霉素 辛基[(3S,6S,9S,12S,15S,21S,24S,27R,33aS)-12,15-二[(2S)-丁烷-2-基]-24-(4-甲氧苄基)-2,8,11,14,20,27-六甲基-1,4,7,10,13,16,19,22,25,28-十羰基-3,6,21-三(丙烷-2-基)三十二氢吡啶并[1,2-d][1,4,7,10,13,16,19,22,25,28]氧杂九氮杂环三十碳十五烯并 谷胱甘肽磺酸酯 谷氨酰-天冬氨酸 表面活性肽 葫芦脲 水合物 葫芦[7]脲 葚孢霉酯I 荧光减除剂(OBA) 苯甲基3-氨基-3-脱氧-α-D-吡喃甘露糖苷盐酸 苯唑西林钠单水合物 苯乙胺,b-氟-a,b-二苯基- 苯乙胺,4-硝基-,共轭单酸(9CI) 苯丙氨酰-甘氨酰-缬氨酰-苄氧喹甲酯-丙氨酰-苯基丙氨酸甲酯 苯丙氨酰-甘氨酰-组氨酰-苄氧喹甲酯-丙氨酰-苯基丙氨酸甲酯 苯丙氨酰-beta-丙氨酸 苯丁抑制素盐酸盐 苄氧羰基-甘氨酰-肌氨酸 芴甲氧羰基-4-叔丁酯-L-天冬氨酸-(2-羟基-4-甲氧基)苄基-甘氨酸 艾默德斯 腐草霉素 脲-甲醛氨酸酯(1:1:1) 胃酶抑素 A 肠螯素铁 肌肽盐酸盐 肌氨酰-肌氨酸 聚普瑞锌杂质7 罗米地辛 缬氨霉素 绿僵菌素D 绿僵菌素C 绿僵菌素 B